Literature DB >> 5820999

Treatment of parkinsonism with levodopa.

M D Yahr, R C Duvoisin, M J Schear, R E Barrett, M M Hoehn.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 5820999     DOI: 10.1001/archneur.1969.00480160015001

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


× No keyword cloud information.
  112 in total

1.  Correction of a rat model of Parkinson's disease by coexpression of tyrosine hydroxylase and aromatic amino acid decarboxylase from a helper virus-free herpes simplex virus type 1 vector.

Authors:  Mei Sun; Guo-Rong Zhang; Lingxin Kong; Courtney Holmes; Xiaodan Wang; Wei Zhang; David S Goldstein; Alfred I Geller
Journal:  Hum Gene Ther       Date:  2003-03-20       Impact factor: 5.695

Review 2.  Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of l-DOPA treatment.

Authors:  Karen L Eskow Jaunarajs; Mariana Angoa-Perez; Donald M Kuhn; Christopher Bishop
Journal:  Neurosci Biobehav Rev       Date:  2010-07-06       Impact factor: 8.989

Review 3.  The on-off phenomenon.

Authors:  A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-06       Impact factor: 10.154

4.  Failure of pyridoxine to reduce drug-induced dyskinesias.

Authors:  G E Crane; I S Turek; A A Kurland
Journal:  J Neurol Neurosurg Psychiatry       Date:  1970-08       Impact factor: 10.154

5.  Dopamine receptors in the substantia nigra are involved in the regulation of muscle tone.

Authors:  K L Double; A D Crocker
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

6.  L-dopa and arousal.

Authors:  T B Horvath; R A Meares
Journal:  J Neurol Neurosurg Psychiatry       Date:  1974-04       Impact factor: 10.154

7.  Attempted use of haloperidol in the treatment of L-dopa induced dyskinesias.

Authors:  H L Klawans; W J Weiner
Journal:  J Neurol Neurosurg Psychiatry       Date:  1974-04       Impact factor: 10.154

Review 8.  Combination therapies: The next logical Step for the treatment of synucleinopathies?

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Mov Disord       Date:  2015-09-21       Impact factor: 10.338

9.  Levodopa-induced dyskinesia and thalamotomy.

Authors:  H Narabayashi; F Yokochi; Y Nakajima
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-08       Impact factor: 10.154

10.  Dopamine/L-dopa ratio in cerebrospinal fluid of parkinsonian patients treated with L-dopa + benserazide.

Authors:  M Fekete; M Tárczy; K Bihari; G Katona
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.